Friday, August 21, 2026
60 articles analyzed
Updated Aug 21, 6:38 PM · 60 sources analyzed
Key Takeaways
Merck terminated its Phase 3 LEAP-014 triplet in esophageal ESCC, another blow to the pembrolizumab-lenvatinib combination strategy.
AbbVie's emraclidine long-term schizophrenia extension study was terminated, raising questions about the Cerevel CNS franchise's near-term value.
Pharvaris discontinued its Phase 2 HAE prophylaxis dose-ranging study, a meaningful setback for the small-cap company's lead program.
🏆 Winner
Viridian Therapeutics — three Phase 3 veligrotug studies in thyroid eye disease completed, setting up a potential BLA filing against Tepezza.
📉 Loser
Pharvaris — termination of the Phase 2 HAE prophylaxis dose-ranging study removes the clearest path to a pivotal trial for its lead asset.
🔭 Watch Next
Viridian Therapeutics' full Phase 3 veligrotug data presentation at an upcoming endocrinology or ophthalmology congress will determine whether the drug's profile justifies a BLA submission and can challenge teprotumumab commercially.
Merck's LEAP-014 triplet terminated in esophageal cancer
Merck discontinued its Phase 3 LEAP-014 trial evaluating pembrolizumab plus lenvatinib plus chemotherapy in first-line metastatic esophageal squamous cell carcinoma, according to ClinicalTrials.gov. The termination signals that adding lenvatinib (a VEGFR inhibitor) to an already-active pembrolizumab-chemotherapy backbone did not justify continued study — a notable stumble for a high-priority oncology combination. The result reinforces that the esophageal ESCC space, where pembrolizumab-chemo is already standard, is proving resistant to easy triplet improvements, narrowing the runway for similar VEGFR-IO combinations across GI cancers.
ClinicalTrials.gov ↗Merck Sharp & Dohme
Pembrolizumab + Lenvatinib + Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma (first-line)
The LEAP-014 trial (NCT04949256) has been terminated. No efficacy data have been released; the registry update reflects trial discontinuation without disclosure of numerical outcomes.
Why it matters
This is the latest in a string of LEAP program disappointments and raises questions about the durability of the lenvatinib-pembrolizumab franchise beyond renal cell and endometrial cancer. Investors should watch whether Merck retrenches the LEAP strategy or doubles down on selected indications with stronger biological rationale.
What to watch
Watch for Merck's investor day commentary on the LEAP program's remaining trials and whether any additional ESCC combinations — including from competitors like BMS with nivolumab-based regimens — fill the void at ESMO GI 2027.
AbbVie
Emraclidine (CVL-231) in Schizophrenia
The long-term safety and tolerability extension study of oral emraclidine in adult schizophrenia patients (NCT05443724) has been terminated. No outcome data were disclosed in the registry update.
Why it matters
AbbVie acquired emraclidine through its Cerevel Therapeutics purchase and the drug had been watched as a next-generation CNS asset. Termination of the OLE — before long-term data could build confidence — suggests either safety signals, strategic reprioritization, or disappointing short-term data that never fully surfaced publicly. The CNS pipeline story at AbbVie may need a new anchor.
What to watch
Watch for AbbVie's Q3 2026 earnings call for any pipeline update addressing emraclidine's status and whether other Cerevel-derived CNS assets (e.g., tavapadon for Parkinson's) are being prioritized in its place.
Pharvaris
PHA-022121 (deucrictibant) in Hereditary Angioedema Type I and II (prophylaxis)
The dose-ranging Phase 2 prophylaxis study of oral PHA-022121 in hereditary angioedema (NCT05047185) has been terminated. Numerical efficacy or safety data were not disclosed in the registry update.
Why it matters
Pharvaris is a small-cap company for which this program represented a core value driver; termination of the prophylaxis dose-ranging study — the study designed to select the dose for a pivotal trial — is a material setback that could force a strategic pivot or partnership discussion. The acute attack treatment program remains a potential lifeline, but prophylaxis was the larger commercial opportunity.
What to watch
Watch for a Pharvaris corporate update or investor communication clarifying whether the termination reflects a strategic pivot to the on-demand acute treatment arm or signals broader program challenges, expected in coming weeks.
Viridian Therapeutics
Veligrotug (VRDN-001) in Thyroid Eye Disease (chronic and active)
Three separate Viridian Phase 3 studies of veligrotug in thyroid eye disease — including the chronic TED study (NCT06021054), the randomized safety/tolerability study (NCT06384547), and the active TED study (NCT05176639) — are now listed as completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in these registry updates.
Why it matters
Three simultaneous Phase 3 completions suggest Viridian is at or near the point of compiling a BLA submission for veligrotug. The competitive question is whether veligrotug's profile — including subcutaneous delivery and dosing convenience — is differentiated enough from Tepezza to capture meaningful market share. Full data disclosure at a medical meeting will be the real inflection point.
What to watch
Watch for Viridian's full Phase 3 data presentation at an endocrinology or ophthalmology congress, and any BLA filing announcement expected in the next one to two quarters.
The LEAP-014 trial (NCT04949256) has been terminated. No efficacy data have been released; the registry update reflects trial discontinuation without disclosure of numerical outcomes.
Why it matters
Lenvatinib's value-add over pembrolizumab-chemotherapy doublet in ESCC is now in serious doubt, tightening the competitive field to agents with distinct mechanisms.
Analysis
This is the latest in a string of LEAP program disappointments and raises questions about the durability of the lenvatinib-pembrolizumab franchise beyond renal cell and endometrial cancer. Investors should watch whether Merck retrenches the LEAP strategy or doubles down on selected indications with stronger biological rationale.
What to watch
Watch for Merck's investor day commentary on the LEAP program's remaining trials and whether any additional ESCC combinations — including from competitors like BMS with nivolumab-based regimens — fill the void at ESMO GI 2027.
The long-term safety and tolerability extension study of oral emraclidine in adult schizophrenia patients (NCT05443724) has been terminated. No outcome data were disclosed in the registry update.
Why it matters
Emraclidine was positioned as a potential muscarinic agonist alternative to dopamine-blocking antipsychotics; termination of the long-term extension casts uncertainty over AbbVie's schizophrenia pipeline differentiation story.
Analysis
AbbVie acquired emraclidine through its Cerevel Therapeutics purchase and the drug had been watched as a next-generation CNS asset. Termination of the OLE — before long-term data could build confidence — suggests either safety signals, strategic reprioritization, or disappointing short-term data that never fully surfaced publicly. The CNS pipeline story at AbbVie may need a new anchor.
What to watch
Watch for AbbVie's Q3 2026 earnings call for any pipeline update addressing emraclidine's status and whether other Cerevel-derived CNS assets (e.g., tavapadon for Parkinson's) are being prioritized in its place.
The dose-ranging Phase 2 prophylaxis study of oral PHA-022121 in hereditary angioedema (NCT05047185) has been terminated. Numerical efficacy or safety data were not disclosed in the registry update.
Why it matters
Oral prophylaxis for hereditary angioedema is a commercially attractive target given the burden of current subcutaneous or IV regimens, but Pharvaris now faces questions about its lead asset's path forward in this indication.
Analysis
Pharvaris is a small-cap company for which this program represented a core value driver; termination of the prophylaxis dose-ranging study — the study designed to select the dose for a pivotal trial — is a material setback that could force a strategic pivot or partnership discussion. The acute attack treatment program remains a potential lifeline, but prophylaxis was the larger commercial opportunity.
What to watch
Watch for a Pharvaris corporate update or investor communication clarifying whether the termination reflects a strategic pivot to the on-demand acute treatment arm or signals broader program challenges, expected in coming weeks.
Three separate Viridian Phase 3 studies of veligrotug in thyroid eye disease — including the chronic TED study (NCT06021054), the randomized safety/tolerability study (NCT06384547), and the active TED study (NCT05176639) — are now listed as completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in these registry updates.
Why it matters
Completion of all three pivotal Phase 3 studies positions Viridian to compile a regulatory package for veligrotug, entering a market currently served by Amgen/Horizon's teprotumumab (Tepezza).
Analysis
Three simultaneous Phase 3 completions suggest Viridian is at or near the point of compiling a BLA submission for veligrotug. The competitive question is whether veligrotug's profile — including subcutaneous delivery and dosing convenience — is differentiated enough from Tepezza to capture meaningful market share. Full data disclosure at a medical meeting will be the real inflection point.
What to watch
Watch for Viridian's full Phase 3 data presentation at an endocrinology or ophthalmology congress, and any BLA filing announcement expected in the next one to two quarters.
The proof-of-concept Phase 2 study of batoclimab — an anti-FcRn antibody (a therapy that lowers pathogenic IgG antibodies by blocking their recycling receptor) — in Graves' disease (NCT05907668) is now listed as completed. No efficacy or safety data have been disclosed in the registry update.
Why it matters
Completion of this POC study is a necessary step before Immunovant can commit to a pivotal program in Graves' disease, a condition driven by pathogenic TSH-receptor antibodies that batoclimab is designed to deplete.
Analysis
Immunovant has been building a multi-indication FcRn franchise; positive POC data in Graves' would broaden the addressable market and reinforce the platform's value beyond myasthenia gravis and CIDP, where competition from argenx and UCB is intense. The absence of data disclosure means investors cannot yet update models, but the study's completion keeps this optionality alive.
What to watch
Watch for Immunovant's next pipeline update or scientific conference presentation where Graves' disease POC data from this study are expected to be disclosed — likely at an endocrine or immunology meeting in H2 2026 or early 2027.
Selective CD28 costimulation blockade restrains IBD T-cell activity without impairing CTLA-4
A bioRxiv preprint reports identification of a small molecule that selectively blocks CD28 costimulation — a key signal that activates pathogenic T cells — in inflammatory bowel disease models, while preserving CTLA-4 signaling that current biologic B7-blockers (like abatacept) inadvertently suppress.
Why it matters
If the selectivity holds in further validation, this molecule could offer a cleaner immunomodulatory profile than existing co-stimulation biologics, potentially reducing immunosuppression-related side effects that have limited adoption of CTLA-4 pathway drugs in IBD.
Analysis
IBD remains a massive commercial opportunity with significant unmet need in refractory patients. A small molecule with a truly selective CD28 mechanism — if it clears the high bar of demonstrating oral bioavailability and durable in vivo efficacy — would be a differentiated entrant in a market dominated by large biologics. The preprint status means this is early-stage science, but BD teams at companies with IBD franchises should be watching.
What to watch
Watch for peer review publication and any announcement of IND-enabling studies or a company filing around this chemical series, which would confirm translation intent.
Cryo-EM structures of eight anticancer drugs trapping topoisomerase 1 reveal distinct binding modes
A bioRxiv preprint presents high-resolution cryo-EM structures of human topoisomerase 1 (TOP1) trapped in its DNA-cleavage complex by eight different clinical anticancer drugs, revealing drug-specific binding geometries at the enzyme-DNA interface.
Why it matters
Structural clarity on how each clinical TOP1 poison engages its target could accelerate rational design of next-generation TOP1 inhibitors with improved potency, selectivity, or reduced resistance liability — relevant to the growing antibody-drug conjugate (ADC) field, where TOP1 payload camptothecin analogs are now a standard warhead.
Analysis
With TOP1-targeting ADC payloads (like DXd and SN-38) now central to the oncology pipeline at Daiichi Sankyo, AstraZeneca, Gilead, and others, structural data illuminating resistance mechanisms or differential DNA trapping efficiency could inform next-generation payload design. Companies developing ADCs or small molecule TOP1 inhibitors should monitor this work as it advances toward peer review.
What to watch
Watch for peer-reviewed publication and follow-on studies examining whether these structural differences translate into differential resistance profiles or combination synergies in cancer cell lines.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse